Q-omics provides the consensus-scored H2AC17 profile across patient tissues and cancer cell-line models. H2AC17 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, H2AC17 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, H2AC17 RNA expression shows 14,105 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight OV, KIRC, and THYM as cancer lineages where H2AC17 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for H2AC17 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes H2AC17 survival associations across molecular data types. H2AC17 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible H2AC17 RNA expression–survival associations across cancer types. High H2AC17 expression shows unfavorable associations in ESCA, KIRC, HNSC, ACC and PAAD, but favorable associations in OV. The OV Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify OV as the clearest survival context for H2AC17 RNA expression.
This table summarizes H2AC17 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for H2AC17. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. H2AC17 shows higher tumor expression in KIRC, HNSC, LUAD, LUSC, LIHC and KIRP. The KIRC box plot shows higher H2AC17 RNA expression in tumor versus normal tissue (log2 FC = +1.201, t-test p < 0.001).
This table shows molecular features associated with H2AC17 in patient tissues and cancer cell lines. In patient samples, H2AC17 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, H2AC17 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Leukemia.
